This study is for adults with multiple myeloma, a type of blood cancer, who have tried other treatments without success. The research is testing if a special cancer vaccine made from a patient's own cells, called the DC/MM fusion vaccine, works safely with another drug, elranatamab. The DC/MM fusion vaccine tries to help the body’s immune system fight the cancer. Elranatamab is already approved by the FDA for this condition. The study will include up to 25 people and involves receiving the study treatment for up to 12 cycles. Each cycle lasts 28 days, and participants will be monitored for up to 5 years with regular clinic visits, blood tests, imaging scans, and bone marrow checks. Participants must be 18 or older, have specific blood test results, and be able to understand and sign a consent form. Pregnant or breastfeeding women cannot join. Participants must also agree to use birth control during and after the study. If interested, consider the time commitment and medical appointments required.
- Study Duration: Up to 5 years with 12 treatment cycles.
- Visits Needed: Regular clinic visits, scans, and tests.
- Eligibility: Adults with relapsed multiple myeloma, not pregnant.